Engitix Therapeutics
Biotechnology Research • 
London, England, United Kingdom • 51-100 Employees
Company overview
| Headquarters | 21 Lombard Street, London, England EC3V 9AH, GB |
| Phone number | +442045307654 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Drug Discovery, Pancreatic Cancer, Tissue Engineering, Liver Cancer, Liver Fibrosis, Extracellular Matrix, Liver Metastasis |
| Founded | 2016 |
| Employees | 51-100 |
| Socials |
Key Contacts at Engitix Therapeutics
Amélie Fortin
Senior Director, People And Culture
Calum Macleod
Director Of Medicinal Chemistry
Mani Manoj
Senior Director Bioplatforms
Amy Lewis
Director, Fibrosis
Laura Chan
Associate Director Of Operations
Brian Veasy
Senior Director, Portfolio & Program Management
Kovilen Sawmynaden
Director Of Antibody Drug Development
Massimo Pinzani
Co-Founder And Consultant Engitix Theraputics Ltd, London, Uk
Luca Frenguelli
Director Of Biomaterials
Leo Hipkiss
Associate Director
Engitix Therapeutics Email Formats
Engitix Therapeutics uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@engitix.com), used 90.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@engitix.com | 90.7% |
{first initial}.{last name} | j.doe@engitix.com | 9.3% |
About Engitix Therapeutics
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.
Engitix Therapeutics revenue & valuation
| Annual revenue | $7,500,000 |
| Revenue per employee | $137,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $24,000,000 |
| Total funding | $54,000,000 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Engitix Therapeutics has 13 employees across 8 departments.
Departments
Number of employees
Engitix Therapeutics Tech Stack
Discover the technologies and tools that power Engitix Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Web servers
Video players
JavaScript libraries
Hosting
Programming languages
Blogs
Video players
Maps
Databases
Miscellaneous
Performance
Font scripts
New Zealand
Canada
Switzerland
Croatia
France
Frequently asked questions
4.8
40,000 users
